Oral Macrolide Therapy Following Short-term Combination Antibiotic Treatment of Mycobacterium massiliense Lung Disease

Won Jung Koh, Byeong Ho Jeong, Kyeongman Jeon, Su Young Kim, Kyoung Un Park, Hye Yun Park, Hee Jae Huh, Chang Seok Ki, Nam Yong Lee, Seung Heon Lee, Chang Ki Kim, Charles L. Daley, SungJae Shin, Hojoong Kim, O. Jung Kwon

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background Although Mycobacterium massiliense lung disease is increasing in patients with cystic fibrosis and non-cystic fibrosis bronchiectasis, optimal treatment regimens remain largely unknown. This study aimed to evaluate the efficacy of oral macrolide therapy after an initial 2-week course of combination antibiotics for the treatment of M massiliense lung disease. Methods Seventy-one patients received oral macrolides, along with an initial 4-week (n = 28) or 2-week (n = 43) IV amikacin and cefoxitin (or imipenem) treatment. These patients were treated for 24 months (4-week IV group) or for at least 12 months after negative sputum culture conversion (2-week IV group). Results Total treatment duration was longer in the 4-week IV group (median, 23.9 months) than in the 2-week IV group (15.2 months; P < .001). The response rates after 12 months of treatment were 89% for symptoms, 79% for CT scanning, and 100% for negative sputum culture results in the 4-week IV group. In the 2-week IV group, these values were 100% (P = .057), 91% (P = .177), and 91% (P = .147), respectively. Acquired macrolide resistance developed in two patients in the 2-week IV group. Genotyping analyses of isolates from patients who did not achieve negative sputum culture conversion during treatment and from those with positive culture results after successful treatment completion revealed that most episodes were due to reinfection with different genotypes of M massiliense. Conclusions Oral macrolide therapy after an initial 2-week course of combination antibiotics might be effective in most patients with M massiliense lung disease. Trial registry ClinicalTrials.gov; No.: NCT00970801; URL: www.clinicaltrials.gov.

Original languageEnglish
Pages (from-to)1211-1221
Number of pages11
JournalChest
Volume150
Issue number6
DOIs
Publication statusPublished - 2016 Dec 1

Fingerprint

Macrolides
Mycobacterium
Lung Diseases
Anti-Bacterial Agents
Sputum
Therapeutics
Cefoxitin
Bronchiectasis
Amikacin
Imipenem
Cystic Fibrosis
Registries
Fibrosis
Genotype

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Koh, W. J., Jeong, B. H., Jeon, K., Kim, S. Y., Park, K. U., Park, H. Y., ... Kwon, O. J. (2016). Oral Macrolide Therapy Following Short-term Combination Antibiotic Treatment of Mycobacterium massiliense Lung Disease. Chest, 150(6), 1211-1221. https://doi.org/10.1016/j.chest.2016.05.003
Koh, Won Jung ; Jeong, Byeong Ho ; Jeon, Kyeongman ; Kim, Su Young ; Park, Kyoung Un ; Park, Hye Yun ; Huh, Hee Jae ; Ki, Chang Seok ; Lee, Nam Yong ; Lee, Seung Heon ; Kim, Chang Ki ; Daley, Charles L. ; Shin, SungJae ; Kim, Hojoong ; Kwon, O. Jung. / Oral Macrolide Therapy Following Short-term Combination Antibiotic Treatment of Mycobacterium massiliense Lung Disease. In: Chest. 2016 ; Vol. 150, No. 6. pp. 1211-1221.
@article{679ced533f044402b767ee01c146b374,
title = "Oral Macrolide Therapy Following Short-term Combination Antibiotic Treatment of Mycobacterium massiliense Lung Disease",
abstract = "Background Although Mycobacterium massiliense lung disease is increasing in patients with cystic fibrosis and non-cystic fibrosis bronchiectasis, optimal treatment regimens remain largely unknown. This study aimed to evaluate the efficacy of oral macrolide therapy after an initial 2-week course of combination antibiotics for the treatment of M massiliense lung disease. Methods Seventy-one patients received oral macrolides, along with an initial 4-week (n = 28) or 2-week (n = 43) IV amikacin and cefoxitin (or imipenem) treatment. These patients were treated for 24 months (4-week IV group) or for at least 12 months after negative sputum culture conversion (2-week IV group). Results Total treatment duration was longer in the 4-week IV group (median, 23.9 months) than in the 2-week IV group (15.2 months; P < .001). The response rates after 12 months of treatment were 89{\%} for symptoms, 79{\%} for CT scanning, and 100{\%} for negative sputum culture results in the 4-week IV group. In the 2-week IV group, these values were 100{\%} (P = .057), 91{\%} (P = .177), and 91{\%} (P = .147), respectively. Acquired macrolide resistance developed in two patients in the 2-week IV group. Genotyping analyses of isolates from patients who did not achieve negative sputum culture conversion during treatment and from those with positive culture results after successful treatment completion revealed that most episodes were due to reinfection with different genotypes of M massiliense. Conclusions Oral macrolide therapy after an initial 2-week course of combination antibiotics might be effective in most patients with M massiliense lung disease. Trial registry ClinicalTrials.gov; No.: NCT00970801; URL: www.clinicaltrials.gov.",
author = "Koh, {Won Jung} and Jeong, {Byeong Ho} and Kyeongman Jeon and Kim, {Su Young} and Park, {Kyoung Un} and Park, {Hye Yun} and Huh, {Hee Jae} and Ki, {Chang Seok} and Lee, {Nam Yong} and Lee, {Seung Heon} and Kim, {Chang Ki} and Daley, {Charles L.} and SungJae Shin and Hojoong Kim and Kwon, {O. Jung}",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.chest.2016.05.003",
language = "English",
volume = "150",
pages = "1211--1221",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "6",

}

Koh, WJ, Jeong, BH, Jeon, K, Kim, SY, Park, KU, Park, HY, Huh, HJ, Ki, CS, Lee, NY, Lee, SH, Kim, CK, Daley, CL, Shin, S, Kim, H & Kwon, OJ 2016, 'Oral Macrolide Therapy Following Short-term Combination Antibiotic Treatment of Mycobacterium massiliense Lung Disease', Chest, vol. 150, no. 6, pp. 1211-1221. https://doi.org/10.1016/j.chest.2016.05.003

Oral Macrolide Therapy Following Short-term Combination Antibiotic Treatment of Mycobacterium massiliense Lung Disease. / Koh, Won Jung; Jeong, Byeong Ho; Jeon, Kyeongman; Kim, Su Young; Park, Kyoung Un; Park, Hye Yun; Huh, Hee Jae; Ki, Chang Seok; Lee, Nam Yong; Lee, Seung Heon; Kim, Chang Ki; Daley, Charles L.; Shin, SungJae; Kim, Hojoong; Kwon, O. Jung.

In: Chest, Vol. 150, No. 6, 01.12.2016, p. 1211-1221.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Oral Macrolide Therapy Following Short-term Combination Antibiotic Treatment of Mycobacterium massiliense Lung Disease

AU - Koh, Won Jung

AU - Jeong, Byeong Ho

AU - Jeon, Kyeongman

AU - Kim, Su Young

AU - Park, Kyoung Un

AU - Park, Hye Yun

AU - Huh, Hee Jae

AU - Ki, Chang Seok

AU - Lee, Nam Yong

AU - Lee, Seung Heon

AU - Kim, Chang Ki

AU - Daley, Charles L.

AU - Shin, SungJae

AU - Kim, Hojoong

AU - Kwon, O. Jung

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background Although Mycobacterium massiliense lung disease is increasing in patients with cystic fibrosis and non-cystic fibrosis bronchiectasis, optimal treatment regimens remain largely unknown. This study aimed to evaluate the efficacy of oral macrolide therapy after an initial 2-week course of combination antibiotics for the treatment of M massiliense lung disease. Methods Seventy-one patients received oral macrolides, along with an initial 4-week (n = 28) or 2-week (n = 43) IV amikacin and cefoxitin (or imipenem) treatment. These patients were treated for 24 months (4-week IV group) or for at least 12 months after negative sputum culture conversion (2-week IV group). Results Total treatment duration was longer in the 4-week IV group (median, 23.9 months) than in the 2-week IV group (15.2 months; P < .001). The response rates after 12 months of treatment were 89% for symptoms, 79% for CT scanning, and 100% for negative sputum culture results in the 4-week IV group. In the 2-week IV group, these values were 100% (P = .057), 91% (P = .177), and 91% (P = .147), respectively. Acquired macrolide resistance developed in two patients in the 2-week IV group. Genotyping analyses of isolates from patients who did not achieve negative sputum culture conversion during treatment and from those with positive culture results after successful treatment completion revealed that most episodes were due to reinfection with different genotypes of M massiliense. Conclusions Oral macrolide therapy after an initial 2-week course of combination antibiotics might be effective in most patients with M massiliense lung disease. Trial registry ClinicalTrials.gov; No.: NCT00970801; URL: www.clinicaltrials.gov.

AB - Background Although Mycobacterium massiliense lung disease is increasing in patients with cystic fibrosis and non-cystic fibrosis bronchiectasis, optimal treatment regimens remain largely unknown. This study aimed to evaluate the efficacy of oral macrolide therapy after an initial 2-week course of combination antibiotics for the treatment of M massiliense lung disease. Methods Seventy-one patients received oral macrolides, along with an initial 4-week (n = 28) or 2-week (n = 43) IV amikacin and cefoxitin (or imipenem) treatment. These patients were treated for 24 months (4-week IV group) or for at least 12 months after negative sputum culture conversion (2-week IV group). Results Total treatment duration was longer in the 4-week IV group (median, 23.9 months) than in the 2-week IV group (15.2 months; P < .001). The response rates after 12 months of treatment were 89% for symptoms, 79% for CT scanning, and 100% for negative sputum culture results in the 4-week IV group. In the 2-week IV group, these values were 100% (P = .057), 91% (P = .177), and 91% (P = .147), respectively. Acquired macrolide resistance developed in two patients in the 2-week IV group. Genotyping analyses of isolates from patients who did not achieve negative sputum culture conversion during treatment and from those with positive culture results after successful treatment completion revealed that most episodes were due to reinfection with different genotypes of M massiliense. Conclusions Oral macrolide therapy after an initial 2-week course of combination antibiotics might be effective in most patients with M massiliense lung disease. Trial registry ClinicalTrials.gov; No.: NCT00970801; URL: www.clinicaltrials.gov.

UR - http://www.scopus.com/inward/record.url?scp=85002968201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85002968201&partnerID=8YFLogxK

U2 - 10.1016/j.chest.2016.05.003

DO - 10.1016/j.chest.2016.05.003

M3 - Article

VL - 150

SP - 1211

EP - 1221

JO - Chest

JF - Chest

SN - 0012-3692

IS - 6

ER -